Design of a broad-range bacteriophage cocktail that reduces pseudomonas aeruginosa biofilms and treats acute infections in two animal models

Francesca Forti, Dwayne R. Roach, Marco Cafora, Maria E. Pasini, David S. Horner, Ersilia V. Fiscarelli, Martina Rossitto, Lisa Cariani, Federica Briani, Laurent Debarbieux, Daniela Ghisotti

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The alarming diffusion of multidrug-resistant (MDR) bacterial strains requires investigations on nonantibiotic therapies. Among such therapies, the use of bacteriophages (phages) as antimicrobial agents, namely, phage therapy, is a promising treatment strategy supported by the findings of recent successful compassionate treatments in Europe and the United States. In this work, we combined host range and genomic information to design a 6-phage cocktail killing several clinical strains of Pseudomonas aeruginosa, including those collected from Italian cystic fibrosis (CF) patients, and analyzed the cocktail performance. We demonstrated that the cocktail composed of four novel phages (PYO2, DEV, E215 and E217) and two previously characterized phages (PAK_P1 and PAK_P4) was able to lyse P. aeruginosa both in planktonic liquid cultures and in biofilms. In addition, we showed that the phage cocktail could cure acute respiratory infection in mice and treat bacteremia in wax moth (Galleria mellonella) larvae. Furthermore, administration of the cocktail to larvae prior to bacterial infection provided prophylaxis. In this regard, the efficiency of the phage cocktail was found to be unaffected by the MDR or mucoid phenotype of the pseudomonal strain. The cocktail was found to be superior to the individual phages in destroying biofilms and providing a faster treatment in mice. We also found the Galleria larva model to be cost-effective for testing the susceptibility of clinical strains to phages, suggesting that it could be implemented in the frame of developing personalized phage therapies.

Original languageEnglish
Article numbere02573-17
JournalAntimicrobial Agents and Chemotherapy
Volume62
Issue number6
DOIs
Publication statusPublished - Jun 1 2018

Fingerprint

Biofilms
Bacteriophages
Pseudomonas aeruginosa
Animal Models
Infection
Larva
Bacteriophage P1
Moths
Waxes
Host Specificity
Therapeutics
Bacteremia
Anti-Infective Agents
Bacterial Infections
Cystic Fibrosis
Respiratory Tract Infections
Phenotype
Costs and Cost Analysis
Phage Therapy

Keywords

  • Bacteriophages
  • Cystic fibrosis
  • Galleria mellonella
  • Phage therapy
  • Pseudomonas aeruginosa

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Design of a broad-range bacteriophage cocktail that reduces pseudomonas aeruginosa biofilms and treats acute infections in two animal models. / Forti, Francesca; Roach, Dwayne R.; Cafora, Marco; Pasini, Maria E.; Horner, David S.; Fiscarelli, Ersilia V.; Rossitto, Martina; Cariani, Lisa; Briani, Federica; Debarbieux, Laurent; Ghisotti, Daniela.

In: Antimicrobial Agents and Chemotherapy, Vol. 62, No. 6, e02573-17, 01.06.2018.

Research output: Contribution to journalArticle

Forti, Francesca ; Roach, Dwayne R. ; Cafora, Marco ; Pasini, Maria E. ; Horner, David S. ; Fiscarelli, Ersilia V. ; Rossitto, Martina ; Cariani, Lisa ; Briani, Federica ; Debarbieux, Laurent ; Ghisotti, Daniela. / Design of a broad-range bacteriophage cocktail that reduces pseudomonas aeruginosa biofilms and treats acute infections in two animal models. In: Antimicrobial Agents and Chemotherapy. 2018 ; Vol. 62, No. 6.
@article{9007644d073947e6928d2a0bd52f6c0c,
title = "Design of a broad-range bacteriophage cocktail that reduces pseudomonas aeruginosa biofilms and treats acute infections in two animal models",
abstract = "The alarming diffusion of multidrug-resistant (MDR) bacterial strains requires investigations on nonantibiotic therapies. Among such therapies, the use of bacteriophages (phages) as antimicrobial agents, namely, phage therapy, is a promising treatment strategy supported by the findings of recent successful compassionate treatments in Europe and the United States. In this work, we combined host range and genomic information to design a 6-phage cocktail killing several clinical strains of Pseudomonas aeruginosa, including those collected from Italian cystic fibrosis (CF) patients, and analyzed the cocktail performance. We demonstrated that the cocktail composed of four novel phages (PYO2, DEV, E215 and E217) and two previously characterized phages (PAK_P1 and PAK_P4) was able to lyse P. aeruginosa both in planktonic liquid cultures and in biofilms. In addition, we showed that the phage cocktail could cure acute respiratory infection in mice and treat bacteremia in wax moth (Galleria mellonella) larvae. Furthermore, administration of the cocktail to larvae prior to bacterial infection provided prophylaxis. In this regard, the efficiency of the phage cocktail was found to be unaffected by the MDR or mucoid phenotype of the pseudomonal strain. The cocktail was found to be superior to the individual phages in destroying biofilms and providing a faster treatment in mice. We also found the Galleria larva model to be cost-effective for testing the susceptibility of clinical strains to phages, suggesting that it could be implemented in the frame of developing personalized phage therapies.",
keywords = "Bacteriophages, Cystic fibrosis, Galleria mellonella, Phage therapy, Pseudomonas aeruginosa",
author = "Francesca Forti and Roach, {Dwayne R.} and Marco Cafora and Pasini, {Maria E.} and Horner, {David S.} and Fiscarelli, {Ersilia V.} and Martina Rossitto and Lisa Cariani and Federica Briani and Laurent Debarbieux and Daniela Ghisotti",
year = "2018",
month = "6",
day = "1",
doi = "10.1128/AAC.02573-17",
language = "English",
volume = "62",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Design of a broad-range bacteriophage cocktail that reduces pseudomonas aeruginosa biofilms and treats acute infections in two animal models

AU - Forti, Francesca

AU - Roach, Dwayne R.

AU - Cafora, Marco

AU - Pasini, Maria E.

AU - Horner, David S.

AU - Fiscarelli, Ersilia V.

AU - Rossitto, Martina

AU - Cariani, Lisa

AU - Briani, Federica

AU - Debarbieux, Laurent

AU - Ghisotti, Daniela

PY - 2018/6/1

Y1 - 2018/6/1

N2 - The alarming diffusion of multidrug-resistant (MDR) bacterial strains requires investigations on nonantibiotic therapies. Among such therapies, the use of bacteriophages (phages) as antimicrobial agents, namely, phage therapy, is a promising treatment strategy supported by the findings of recent successful compassionate treatments in Europe and the United States. In this work, we combined host range and genomic information to design a 6-phage cocktail killing several clinical strains of Pseudomonas aeruginosa, including those collected from Italian cystic fibrosis (CF) patients, and analyzed the cocktail performance. We demonstrated that the cocktail composed of four novel phages (PYO2, DEV, E215 and E217) and two previously characterized phages (PAK_P1 and PAK_P4) was able to lyse P. aeruginosa both in planktonic liquid cultures and in biofilms. In addition, we showed that the phage cocktail could cure acute respiratory infection in mice and treat bacteremia in wax moth (Galleria mellonella) larvae. Furthermore, administration of the cocktail to larvae prior to bacterial infection provided prophylaxis. In this regard, the efficiency of the phage cocktail was found to be unaffected by the MDR or mucoid phenotype of the pseudomonal strain. The cocktail was found to be superior to the individual phages in destroying biofilms and providing a faster treatment in mice. We also found the Galleria larva model to be cost-effective for testing the susceptibility of clinical strains to phages, suggesting that it could be implemented in the frame of developing personalized phage therapies.

AB - The alarming diffusion of multidrug-resistant (MDR) bacterial strains requires investigations on nonantibiotic therapies. Among such therapies, the use of bacteriophages (phages) as antimicrobial agents, namely, phage therapy, is a promising treatment strategy supported by the findings of recent successful compassionate treatments in Europe and the United States. In this work, we combined host range and genomic information to design a 6-phage cocktail killing several clinical strains of Pseudomonas aeruginosa, including those collected from Italian cystic fibrosis (CF) patients, and analyzed the cocktail performance. We demonstrated that the cocktail composed of four novel phages (PYO2, DEV, E215 and E217) and two previously characterized phages (PAK_P1 and PAK_P4) was able to lyse P. aeruginosa both in planktonic liquid cultures and in biofilms. In addition, we showed that the phage cocktail could cure acute respiratory infection in mice and treat bacteremia in wax moth (Galleria mellonella) larvae. Furthermore, administration of the cocktail to larvae prior to bacterial infection provided prophylaxis. In this regard, the efficiency of the phage cocktail was found to be unaffected by the MDR or mucoid phenotype of the pseudomonal strain. The cocktail was found to be superior to the individual phages in destroying biofilms and providing a faster treatment in mice. We also found the Galleria larva model to be cost-effective for testing the susceptibility of clinical strains to phages, suggesting that it could be implemented in the frame of developing personalized phage therapies.

KW - Bacteriophages

KW - Cystic fibrosis

KW - Galleria mellonella

KW - Phage therapy

KW - Pseudomonas aeruginosa

UR - http://www.scopus.com/inward/record.url?scp=85047635775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047635775&partnerID=8YFLogxK

U2 - 10.1128/AAC.02573-17

DO - 10.1128/AAC.02573-17

M3 - Article

AN - SCOPUS:85047635775

VL - 62

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

M1 - e02573-17

ER -